Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The concept of a super-aged society has led to a steady increase in the average lifespan and hence, interest in a healthy life has increased. Aging is a major risk factor for many diseases, including osteoporosis. Osteoporotic fractures have a significant impact on the quality of life of the elderly and hence, it is pivotal to provide effective treatment of osteoporosis after menopause. Osteoporosis requires proper management and the treatment must be centered on long-term goals. New drugs with diverse mechanisms have been developed for treating osteoporosis. Current management of osteoporosis generally focuses on the importance of risk-based strategies to maximize the effectiveness of existing treatments and mitigate potential negative side-effects. Additionally, there is a need for sequential treatment of osteoporosis in the future. This review discusses the dynamic strategies for osteoporosis treatment and the importance of long-term management in postmenopausal women.
Abstract
The concept of a super-aged society has led to a steady increase in the average lifespan and hence, interest in a healthy life has increased. Aging is a major risk factor for many diseases, including osteoporosis. Osteoporotic fractures have a significant impact on the quality of life of the elderly and hence, it is pivotal to provide effective treatment of osteoporosis after menopause. Osteoporosis requires proper management and the treatment must be centered on long-term goals. New drugs with diverse mechanisms have been developed for treating osteoporosis. Current management of osteoporosis generally focuses on the importance of risk-based strategies to maximize the effectiveness of existing treatments and mitigate potential negative side-effects. Additionally, there is a need for sequential treatment of osteoporosis in the future. This review discusses the dynamic strategies for osteoporosis treatment and the importance of long-term management in postmenopausal women.
참고문헌 (28)
- "OECD health statistics 2021" (2021)[URL]
- 김윤미, "골다공증 유병률, 인지율, 치료율 및 영향요인의 성별 비교: 국민건강영양조사 자료(2008~2011년) 활용", Journal of Korean Academy of Nursing, 45(2), pp.293~305 (2015), 한국간호과학회
- "Healthcare statistics data. Healthcare statistics per disease/behavior. High-interest diseases. Osteoporosis"[URL]
- Hassan N, "Anabolic treatments for osteoporosis in postmenopausal women", Fac Rev, 10, pp.44~ (2021)
- Langdahl BL, "Overview of treatment approaches to osteoporosis", Br J Pharmacol, 178, pp.1891~1906 (2021)
- Shoback D, "Pharmacological management of osteoporosis in postmenopausal women : An Endocrine Society Guideline update", J Clin Endocrinol Metab, 105, pp.dgaa048~ (2020)
- Banefelt J, "Risk of imminent fracture following a previous fracture in a Swedish database study", Osteoporos Int, 30, pp.601~609 (2019)
- Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020update, 2020, pp.26(Suppl 1), 1~46
- Barrionuevo P, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women : a network meta-analysis", J Clin Endocrinol Metab, 104, pp.1623~1630 (2019)
- Delmas PD, "Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial", J Clin Endocrinol Metab, 87, pp.3609~3617 (2002)
- Silverman SL, "Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis : results from a 3-year, randomized, placebo-, and activecontrolled clinical trial", J Bone Miner Res, 23, pp.1923~1934 (2008)
- Eastell R, "Pharmacological management of osteoporosis in postmenopausal women : An Endocrine Society* Clinical Practice guideline", J Clin Endocrinol Metab, 104, pp.1595~1622 (2019)
- Kamimura M, "Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonateunresponsive patients", Osteoporos Int, 28, pp.559~566 (2017)
- Miller PD, "Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates", Osteoporos Int, 31, pp.181~191 (2020)
- Anastasilakis AD, "Denosumab discontinuation and the rebound phenomenon : a narrative review", J Clin Med, 10, pp.152~ (2021)
- Freemantle N, "Final results of the DAPS(Denosumab Adherence Preference Satisfaction)study : a 24-month, randomized, crossover comparison with alendronate in postmenopausal women", Osteoporos Int, 23, pp.317~326 (2012)
- Kendler D, "Bone mineral density after transitioning from denosumab to alendronate", J Clin Endocrinol Metab, 105, pp.e255~e264 (2020)
- Everts-Graber J, "A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains", J Bone Miner Res, 35, pp.1207~1215 (2020)
- Ebina K, "The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis", J Bone Miner Metab, 35, pp.91~98 (2017)
- Cosman F, "Romosozumab treatment in postmenopausal women with osteoporosis", N Engl J Med, 375, pp.1532~1543 (2016)
- Cosman F, "Romosozumab and antiresorptive treatment : the importance of treatment sequence", Osteoporos Int, 33, pp.1243~1256 (2022)
- Saag KG, "Romosozumab or alendronate for fracture prevention in women with osteoporosis", N Engl J Med, 377, pp.1417~1427 (2017)
- Cosman F, "FRAME Study : the foundation effect of building bone with 1 Year of romosozumab leads to continued lower fracture risk after transition to denosumab", J Bone Miner Res, 33, pp.1219~1226 (2018)
- Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial", Lancet, 386, pp.1147~1155 (2015)
- McClung MR, "Skeletal responses to romosozumab after 12 months of denosumab", JBMR Plus, 5, pp.e10512~ (2021)
- Ebina K, "Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis", Bone, 140, pp.115574~ (2020)
- Kobayakawa T, "Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients : a prospective cohort study", Bone Rep, 14, pp.101068~ (2021)
- Laura I, "Which treatment to prevent an imminent fracture?", Bone Rep, 15, pp.101105~ (2021)